@admin / longevity-researchmission

Longevity Research

Succeeded
Elapsed
375.7s
Cost
Free
Tokens
0
0 in · 0 out
Events
28
click to inspect
live output
Starting mission longevity-research…
==> Longevity-research mission tick starting
==> Goal: Anchor the first human-validated causal relation in the mTORC1–autophagy–inflammaging axis by pursuing a dual-track stra
── Phase 1: Director
==> Swarm tick starting. KB: {'entities': 142, 'relations': 0}
Focus: FOCUS AREAS:
1. Rare protein-truncating variant (PTV) and cis-eQTL drug-target Mendelian randomization of *RPTOR* against plasma IL-6 and hs-CRP in UK Biobank/FinnGen, exploiting *RPTOR*'s strict mTO
── Phase 2: Scouts
[opentargets] fetched 0 items
[opentargets] error: HTTP Error 400: Bad Request
[clinicaltrials] fetched 0 items
[europepmc] fetched 60 items
[biorxiv] fetched 30 items
[medrxiv] fetched 30 items
[pubmed] esearch error: <urlopen error [Errno -3] Temporary failure in name resolution>
[pubmed] fetched 0 items
── Phase 3: Synthesizer
Items: 120
── Phase 4: Critic
── Phase 5: Curator
Findings: 0, Hypotheses: 3
── Phase 6: Reporter
── Phase 7: Director-meta
==> Tick complete. Findings: 0, Hypotheses: 3
==> Tick complete.
Outputs
{
  "result": " This tick, the Gonka Labs swarm zeroed in on a tightly scoped question: can we isolate mTORC1’s specific contribution to age-related inflammation—dubbed inflammaging—without the confounding shadow of its sibling complex, mTORC2? Rather than surveying the entire longevity landscape, the mission deliberately narrowed its aperture to the *RPTOR* gene, which encodes a subunit found exclusively in mTORC1. The planned triangulation included Mendelian randomization using protein-truncating and regulatory variants in UK Biobank and FinnGen, trans-ethnic fine-mapping across East Asian and European cohorts to strip out metabolic pleiotropy, and CRISPRi perturbation in iPSC-derived macrophages paired with everolimus to trace autophagy-dependent signaling. Notably, this tick yielded **zero new empirical relations** for the knowledge base; the work was foundational, mapping how to rigorously test the hypothesis rather than producing evidence for or against it.\n\nThe central mechanistic bet is that mTORC1 acts as a cellular nutrient checkpoint. When mTORC1 is chronically overactive—as may happen with aging—it clamps down on autophagy, the cell’s recycling and quality-control program. The swarm hypothesizes that by genetically or pharmacologically throttling mTORC1 specifically via *RPTOR*, macrophages could reactivate transcription factors TFEB and TFE3, restore autophagic flux, and sequester the inflammatory master-switch NF-κB p65 in the cytosol, thereby lowering secretion of IL-6 and hs-CRP. This would provide a causal bridge from nutrient sensing to sterile inflammation. It is an elegant model, but at this stage it remains precisely that—a model; no new cellular or genetic data were generated this tick to confirm or refute any step in the proposed chain.\n\n**Evidence strength:** none produced this tick. The knowledge base holds 142 entities but zero causal relations. The recently ingested literature provides broad geroscience context—spanning economic frameworks, historical anti-aging strategies, and senescence in kidney disease—but offers no direct human, animal, or in vitro evidence for the *RPTOR*–autophagy–IL-6 axis. The mission is therefore standing on well-trodden pharmacological ground (rapalogs like everolimus are known to modulate immunity and inflammation) but lacks the orthogonal genetic and experimental causal edges required to move from drug observation to target validation. Until the planned Mendelian randomization and macrophage assays execute, confidence rests on indirect precedent rather than de novo findings.\n\n**Outstanding questions** are both methodological and biological. First, will *RPTOR* genetic instruments remain valid after conditioning on BMI, fasting insulin, and LDL, or will metabolic pleiotropy erase the inflammatory signal? Second, can trans-ethnic fine-mapping in Biobank Japan and UK Biobank identify linkage-disequilibrium-independent variants strong enough for multivariable MR? And third, in human macrophages, is autophagy truly the required intermediary—will *ATG7*-mediated blockade abolish the mTORC1–NF-κB coupling, or will IL-6 suppression persist via an alternate route? The swarm has rightly deprioritized broader cytokine panels, clinical trajectory analyses (such as PEARL/EXIST), and non-mTOR pathways until this first causal edge is anchored.\n\nOverall, the direction is scientifically sound and strategically disciplined. The choice to exploit *RPTOR*’s strict mTORC1-specificity to circumvent mTORC2 confounding reflects a rigorous attempt to solve a known analytical problem in the field. However, honest assessment demands acknowledging that this tick produced no new data; the mission is still in the launch phase. If the upcoming genetic and iPSC experiments converge, the payoff could be a precise, genetically validated lever for dampening inflammaging. If they diverge, the swarm will need to rethink whether mTORC1’s link to IL-6 is direct, metabolic, or non-causal.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}
Inference calls7